Research programme: casein kinase 1 inhibitors - CasInvent Pharma
Alternative Names: CS1 inhibitors - CasInvent PharmaLatest Information Update: 24 Apr 2024
At a glance
- Originator Masaryk University
- Developer CasInvent Pharma
- Class Antineoplastics; Imidazoles; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Casein kinase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Colorectal cancer; Malignant melanoma; Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 24 Apr 2024 Early research in Colorectal cancer in Czech Republic (unspecified route) (CasInvent Pharma pipeline, April 2024)
- 24 Apr 2024 Early research in Malignant melanoma in Czech Republic (unspecified route) (CasInvent Pharma pipeline, April 2024)
- 24 Apr 2024 Early research in Pancreatic cancer in Czech Republic (unspecified route) (CasInvent Pharma pipeline, April 2024)